data
success
attenu
lentivir
vaccin
studi
indic
fulli
matur
envspecif
antibodi
character
high
titer
high
avid
predomin
recognit
conform
epitop
associ
protect
efficaci
although
vaccin
dna
primerecombin
vacciniavector
vaccin
boost
strategi
found
effect
trial
nonhuman
primatesimianhuman
immunodefici
viru
shiv
model
remain
unclear
whether
vaccin
strategi
could
elicit
matur
equin
infecti
anemia
viru
eiav
envspecif
antibodi
thu
protect
vaccin
hors
eiav
infect
therefor
pilot
studi
vaccin
hors
use
strategi
base
dna
primerecombin
tiantan
vaccinia
rttv
vector
vaccin
encod
eiav
env
gag
gene
observ
develop
envspecif
antibodi
neutral
antibodi
antibodi
vaccin
dna
induc
low
titer
low
avid
predomin
recognit
linear
epitop
envspecif
antibodi
enhanc
boost
vaccin
rttv
vaccin
howev
matur
level
envspecif
antibodi
induc
dnarttv
vaccin
significantli
lower
induc
attenu
vaccin
eiav
fddv
addit
dnarttv
vaccin
elicit
broadli
neutral
antibodi
challeng
virul
eiav
strain
vaccine
control
hors
die
eiav
diseas
data
indic
regimen
dna
primerttv
vaccin
boost
induc
matur
envspecif
antibodi
might
contribut
immun
protect
failur
e
quin
infecti
anemia
viru
eiav
macrophagetrop
lentiviru
caus
persist
infect
equid
infect
character
recur
febril
episod
associ
viremia
fever
thrombocytopenia
wast
symptom
past
varieti
eiav
experiment
vaccin
develop
includ
inactiv
whole
viru
vaccin
particul
viral
protein
vaccin
recombin
envelop
subunit
vaccin
dna
vaccin
encod
gene
conserv
cellular
target
epitop
gag
attenu
vaccin
gener
molecular
clone
provir
genom
serial
passag
host
cell
protect
efficaci
confer
vaccin
rang
steril
protect
protect
diseas
death
signific
enhanc
eiav
replic
diseas
thu
far
success
effect
immun
protect
observ
anim
vaccin
attenu
vaccin
result
make
attenu
vaccin
good
standard
test
vaccin
strategi
seri
studi
success
attenu
eiav
vaccin
eiav
demonstr
combin
fulli
matur
envspecif
antibodi
high
titer
high
avid
preferenti
recognit
conform
epitop
cellulartarget
env
epitop
associ
protect
efficaci
studi
suggest
eiav
vaccin
candid
capabl
induc
matur
humor
potent
cellular
immun
respons
env
achiev
effect
protect
contrast
recombin
subunit
inactiv
wholeviru
vaccin
dna
vaccin
viral
vector
vaccin
proven
induc
potent
humor
cellular
immun
respons
encod
viral
protein
express
antigen
authent
conform
util
major
histocompat
complex
mhc
class
class
ii
pathway
present
antigen
host
cell
moreov
vaccin
use
regimen
dna
vaccin
primevir
vector
vaccin
boost
observ
elicit
stronger
humor
cellular
immun
respons
vaccin
either
vaccin
alon
thu
offer
better
protect
vaccine
human
anim
model
howev
far
data
confirm
whether
vaccin
strategi
induc
potent
protectionassoci
immun
respons
hors
thu
confer
effect
protect
eiav
infect
diseas
therefor
pilot
studi
construct
recombin
dna
rdna
recombin
tiantan
vaccinia
rttv
vector
vaccin
encod
eiav
env
gag
gene
vaccin
hors
dna
primerttv
vaccin
boost
strategi
compar
induct
envspecif
antibodi
hors
vaccin
set
vaccin
attenu
chines
eiav
vaccin
fddv
eiav
fddv
final
evalu
protect
efficaci
vaccin
strategi
challeng
vaccine
wildtyp
eiav
strain
eiav
lnv
infecti
clone
deriv
eiav
fddv
env
gag
gene
patent
codon
optim
hors
express
synthes
oligonucleotid
sangon
shanghai
china
gene
sequenc
confirm
sequenc
doubl
strand
sens
antisens
gene
dna
subsequ
clone
express
vector
gener
two
dna
vaccin
addit
two
plasmid
encod
wildtyp
env
gag
gene
respect
construct
control
vitro
express
properti
express
vector
previous
describ
comparison
vitro
express
synthet
eiav
env
gag
gene
correspond
wildtyp
gene
vitro
express
synthet
eiav
gene
correspond
wildtyp
gene
compar
western
blot
wb
briefli
lg
transfect
cell
hors
dermal
fibroblast
cell
tissu
cultur
plate
h
cell
collect
lyse
lg
total
cell
lysat
subject
standard
wb
procedur
fig
eiavposit
hors
serum
mous
antihuman
antihors
bactin
monoclon
antibodi
serv
primari
antibodi
horseradish
peroxidas
hrp
conjug
goat
antihors
igg
goat
antimous
igg
fitcconjug
goat
antihors
igg
goat
antimous
igg
use
secondari
antibodi
final
protein
band
visual
use
enhanc
chemiluminesc
fluoresc
scanner
codonoptim
eiav
env
gag
gene
transfer
shuttl
plasmid
lac
z
gene
select
marker
specif
design
recombin
tk
gene
ttv
subconflu
monolay
grown
eagl
medium
contain
fetal
bovin
serum
penicillinstreptomycinlglutamin
cell
wash
eagl
medium
contain
glutamin
antibiot
absenc
fetal
bovin
serum
wildtyp
tiantan
vaccinia
viru
inocul
multipl
infect
moi
incub
h
co
subsequ
vacciniainfect
cell
transfect
recombin
shuttl
plasmid
use
lipofectamin
invitrogen
carlsbad
ca
h
incub
transfect
medium
remov
well
cover
melt
low
melt
temperatur
agaros
mix
equal
volum
eagl
medium
contain
lgml
xgal
blue
lac
zposit
coloni
pick
purifi
select
pressur
eagl
medium
contain
lgml
budr
purifi
recombin
ttv
confirm
pcr
amplif
insert
eiav
env
gag
gene
gener
vaccin
design
rttvenvsyn
rttvgagsyn
rttv
expand
primari
chicken
embryo
fibroblast
cell
confirm
wb
describ
fetal
donkey
dermal
fdd
cell
equin
monocytederiv
macrophag
emdm
cultur
previous
describ
eiav
lnv
highvirul
eiav
strain
use
challeng
strain
studi
use
neutral
antibodi
assay
homolog
vaccin
strain
two
rel
heterolog
virul
variant
eiav
lnv
virul
env
sequenc
describ
previous
mean
diverg
deduc
su
polypeptid
eiav
fddv
eiav
lnv
respect
prepar
titrat
store
previous
describ
four
hors
use
studi
thoroughbr
prior
experi
serum
sampl
collect
hors
test
twice
agar
gel
immunodiffus
test
agid
vmrd
ensur
seroneg
eiav
infect
hors
hous
screen
box
stall
exclud
hematophag
insect
anim
handl
protocol
approv
anim
manag
committe
chines
harbin
veterinari
research
institut
hors
vaccin
intramuscular
inject
mg
mg
mg
site
side
neck
week
vaccin
intraderm
inject
pfu
rttvgagsynrttvenvsyn
site
side
neck
week
fig
hors
inocul
empti
vector
wildtyp
ttv
dose
rout
schedul
hors
challeng
hypoderm
inject
ml
viru
stock
copiesml
viral
rna
eiav
lnv
week
observ
death
sera
collect
week
prior
first
dna
vaccin
prior
first
rttv
vaccin
prior
second
rttv
vaccin
day
prior
eiav
lnv
challeng
whole
blood
plasma
collect
week
challeng
phase
sera
plasma
whole
blood
surviv
hors
collect
day
postchalleng
die
accid
week
sampl
collect
hors
subsequ
hors
hypoderm
vaccin
ml
tcid
eiav
fddv
mo
control
hors
challeng
togeth
rd
day
dose
eiav
lnv
observ
period
postchalleng
present
detect
infect
develop
eia
febril
episod
die
acut
eia
infect
sera
hors
vaccin
eiav
fddv
collect
month
postvaccin
serum
sampl
store
antibodi
assay
plasma
sampl
store
quantit
qualit
analysi
eiav
plasma
whole
blood
sampl
use
platelet
enumer
rectal
temperatur
clinic
statu
surviv
hors
record
twice
per
day
throughout
trial
clinic
episod
eia
defin
thrombocytopenia
plateletsl
whole
blood
occur
fever
rectal
temperatur
concurr
high
level
plasma
viral
rna
quantit
qualit
analys
plasma
viral
genom
perform
previous
describ
serum
immunoglobulin
g
antibodi
reactiv
eiav
fddv
envelop
glycoprotein
quantit
endpoint
titer
qualit
avid
index
conform
ratio
assay
use
standard
cona
elisa
procedur
previous
describ
except
coat
eiav
pv
replac
gradientpurifi
eiav
fddv
endpoint
titer
core
igg
detect
use
standard
elisa
express
e
coli
purifi
sdspage
puriti
data
shown
sampl
consid
posit
sampl
optic
densiti
exceed
mean
optic
densiti
valu
correspond
neg
sampl
preimmun
bleed
plu
two
time
standard
deviat
dilut
sera
heat
inactiv
min
neutral
assay
inactiv
infecti
viru
labil
serum
protein
serum
neutral
activ
homolog
rel
heterolog
viru
strain
assess
modifi
indirect
cell
elisabas
infecti
center
assay
method
use
constant
amount
sequenti
twofold
dilut
serum
previous
describ
serum
neutral
activ
assess
rt
assay
previous
describ
statist
analys
perform
graphpad
prism
version
graphpad
softwar
inc
san
diego
ca
mannwhitney
u
test
use
compar
endpoint
titer
avid
index
conform
ratio
envspecif
antibodi
neutral
activ
serum
sampl
hors
vaccin
rdnarttv
vaccin
attenu
vaccin
eiav
fddv
twotail
p
valu
consid
signific
previou
studi
research
demonstr
codon
optim
dramat
increas
vitro
express
immunogen
eiav
env
gene
dna
vector
therefor
studi
construct
dna
tiantan
vacciniavector
vaccin
encod
codonoptim
eiav
env
gag
gene
shown
fig
b
c
rttvenvsyn
express
env
protein
approxim
kda
rttvgagsyn
express
gag
protein
approxim
kda
dna
vector
tiantan
vaccinia
vector
present
protein
express
lane
sampl
vaccin
encod
env
gene
main
band
locat
approxim
kda
sampl
transfect
cellsinfect
primari
chicken
embryo
fibroblast
cell
kda
sampl
transfect
equin
dermal
cell
one
dimer
band
locat
slightli
kda
could
observ
sampl
hand
band
markedli
thicker
lane
sampl
dna
vector
encod
codonoptim
env
gag
gene
lane
sampl
dna
vector
encod
wildtyp
env
gag
gene
housekeep
gene
bactin
present
compar
express
sampl
transfect
equin
dermal
cell
fig
c
data
indic
construct
dna
vacciniavector
vaccin
correctli
express
encod
eiav
env
gag
gene
codon
optim
significantli
increas
vitro
express
encod
gene
dna
vector
moreov
fulllength
precursor
may
process
su
tm
dna
vaccineexpress
cell
rttv
vaccineinfect
cell
determin
whether
vaccin
strategi
use
dna
primevacciniavector
vaccin
boost
could
induc
protectionassoci
immun
respons
vaccin
hors
plu
time
point
prime
boost
twice
rttvenvsyn
plu
rttvgagsyn
compar
induct
envspecif
antibodi
neutral
antibodi
vaccine
hors
vaccin
attenu
eiav
vaccin
eiav
fddv
vaccin
phase
eiav
fddv
vaccin
hors
protect
infect
protect
death
challeng
eiav
lnv
shown
recent
report
fig
g
j
summar
develop
envspecif
antibodi
neutral
antibodi
homolog
strain
hors
immun
dna
rttv
vaccin
envspecif
antibodi
neutral
antibodi
appear
wk
third
fifth
dna
vaccin
gradual
increas
respect
two
week
sixth
dna
vaccin
mean
endpoint
titer
avid
index
conform
ratio
envspecif
antibodi
mean
neutral
titer
respect
first
boost
vaccin
rttv
vaccin
mean
four
paramet
increas
markedli
week
gradual
decreas
week
day
prior
second
boost
rttv
vaccin
although
envspecif
antibodi
neutral
activ
peak
quickli
wk
second
rttv
vaccin
boost
activ
compar
week
follow
first
rttv
vaccin
boost
addit
activ
gradual
decreas
week
day
prior
challeng
eiav
lnv
contrast
neutral
antibodi
heterogen
virul
strain
observ
entir
vaccin
phase
data
shown
shown
fig
e
h
k
envspecif
antibodi
neutral
activ
detect
mo
postvaccin
eiav
fddv
vaccin
hors
endpoint
titer
avid
index
conform
ratio
envspecif
antibodi
gradual
increas
plateau
mo
postvaccin
reach
mean
sampl
mo
postvaccin
day
prior
challeng
fig
develop
envspecif
antibodi
neutral
antibodi
antibodi
respons
attenu
vaccin
eiav
fddv
dnarecombin
ttvvector
vaccin
longitudin
character
quantit
qualit
properti
eiav
envelopespecif
antibodi
conduct
con
elisa
endpoint
titer
b
avid
e
conform
depend
g
h
describ
text
serum
neutral
activ
j
k
longitudin
analyz
describ
text
longitudin
analysi
endpoint
titer
eiav
igg
antibodi
n
conduct
via
elisa
describ
text
analys
perform
two
trial
group
dnarecombin
ttvvector
vaccin
left
panel
attenu
vaccin
eiav
fddv
right
panel
endpoint
titer
c
avid
f
conform
depend
envspecif
antibodi
neutral
activ
l
endpoint
titer
specif
antibodi
compar
serum
sampl
collect
hors
vaccin
dnarttv
vaccin
wk
follow
boost
rttv
vaccin
hors
vaccin
eiav
fddv
mo
postinocul
serum
antibodi
endpoint
titer
present
log
highest
reciproc
dilut
yield
reactiv
two
standard
deviat
background
avid
index
measur
present
percentag
antibodyantigen
complex
resist
disrupt
urea
conform
depend
valu
calcul
ratio
serum
antibodi
reactiv
nativ
envelop
compar
denatur
envelop
antigen
neutral
activ
present
mean
reciproc
dilut
serum
neutral
input
eiav
viru
measur
infecti
center
assay
describ
text
eiav
lnv
serum
activ
peak
month
remain
constant
day
challeng
addit
induc
high
level
neutral
antibodi
eiav
fddv
also
elicit
neutral
antibodi
vaccin
hors
demonstr
recent
report
day
challeng
mean
neutral
activ
eiav
fddv
vaccin
hors
respect
contrast
develop
envspecif
antibodi
vaccin
dna
vaccin
rapidli
induc
gagspecif
antibodi
vaccine
mean
endpoint
titer
antibodi
increas
wk
first
rttv
vaccin
boost
fig
although
second
rttv
vaccin
boost
improv
endpoint
titer
activ
antibodi
longer
last
envspecif
antibodi
hors
vaccin
dna
rttv
vaccin
fig
day
challeng
mean
endpoint
titer
antibodi
still
high
hors
vaccin
eiav
fddv
endpoint
titer
antibodi
plateau
mo
postvaccin
quickli
declin
remain
low
level
approxim
undetect
day
challeng
fig
compar
activ
envspecif
antibodi
hors
vaccin
eiav
fddv
hors
vaccin
dnarttv
vaccin
period
requir
achiev
rel
matur
envspecif
antibodi
use
respect
immun
regimen
gener
approxim
necessari
develop
matur
envspecif
antibodi
attenu
eiav
vaccin
studi
found
paramet
envspecif
antibodi
plateau
postvaccin
eiav
fddv
peak
rttv
vaccin
boost
therefor
serum
sampl
collect
vaccine
week
postrttv
boost
serum
sampl
collect
vaccine
month
postvaccin
eiav
fddv
select
compar
shown
fig
f
l
endpoint
titer
avid
index
conform
ratio
envspecif
antibodi
neutral
titer
significantli
lower
sampl
hors
vaccin
dnarttv
vaccin
sampl
hors
vaccin
eiav
fddv
howev
endpoint
titer
antibodi
higher
former
sampl
latter
sampl
data
indic
immun
strategi
eiav
dna
primerttv
vaccin
boost
induc
matur
envspecif
antibodi
high
level
broadli
neutral
antibodi
moreov
envspecif
antibodi
neutral
antibodi
induc
strategi
lack
durabl
compar
induc
attenu
vaccin
eiav
fddv
final
evalu
protect
efficaci
confer
dnarttv
vaccin
challeng
two
vaccine
one
empti
vector
control
hors
eiav
lnv
day
hors
vaccin
eiav
fddv
one
control
hors
also
challeng
eiav
lnv
use
dose
rout
serum
plasma
sampl
collect
time
point
challeng
agidand
viral
rnaneg
data
shown
result
indic
vaccine
empti
vector
control
hors
infect
wildtyp
vaccin
eiav
strain
vaccine
enrol
challeng
trial
hors
die
accid
involv
broken
spine
possibl
death
eiav
equin
infecti
diseas
rule
extens
patholog
diagnosi
data
shown
supplement
fig
b
c
depict
clinic
virolog
profil
vaccine
control
hors
postchalleng
observ
period
see
onlin
supplementari
materi
http
wwwliebertpubcom
challeng
quickli
present
viremia
week
postchalleng
minim
viral
load
copi
rnam
sequenc
amplifi
env
fragment
consist
eiav
lnv
develop
acut
eia
diseas
sign
fever
thrombocytopenia
soon
die
week
postchalleng
data
indic
four
hors
die
acut
eiav
infect
dna
vaccin
primerecombin
tiantan
vacciniavector
vaccin
boost
regimen
protect
vaccine
eia
death
hors
vaccin
eiav
fddv
hors
protect
infect
hors
protect
death
postchalleng
observ
period
studi
lentivir
attenu
vaccin
indic
sustain
low
level
antigen
present
consist
stimul
host
immun
system
requir
achiev
sustain
adequ
immun
matur
therebi
effect
protect
vaccine
exposur
lentivirus
result
suggest
eiav
vaccin
dna
vaccin
live
viral
vectorbas
vaccin
might
also
effect
base
regimen
multipl
antigen
exposur
andor
sustain
antigen
present
howev
studi
found
regimen
use
eiav
dna
vaccin
prime
rttv
vaccin
boost
induc
matur
eiav
envspecif
antibodi
broadli
neutral
antibodi
contrast
vaccin
attenu
vaccin
eiav
fddv
induc
immun
respons
fail
protect
vaccine
death
challeng
virul
eiav
strain
cook
et
al
report
dna
encod
codonoptim
eiav
induc
detect
antibodi
poni
vaccin
induc
antibodi
present
neutral
activ
even
homolog
eiav
strain
similarli
studi
observ
success
vaccin
dna
induc
low
titer
low
avid
low
recognit
conform
epitop
transient
igg
respons
env
although
induct
antibodi
high
consist
data
eiav
dna
vaccin
previou
studi
compar
immunogen
hiv
env
influenza
viru
hemagglutinin
glycoprotein
dna
vector
demonstr
multipl
dna
prime
vaccin
achiev
low
titer
transient
antibodi
respons
hiv
env
high
titer
high
avid
persist
igg
respons
influenza
viru
seen
first
dna
vaccin
data
suggest
compar
specif
antibodi
encod
protein
matur
specif
antibodi
lentivir
env
may
difficult
induc
use
dna
vector
even
multipl
subsequ
immun
data
also
suggest
mechan
may
involv
induct
matur
envspecif
antibodi
attenu
lentivir
vaccin
addit
sustain
present
env
antigen
although
first
rttv
vaccin
boost
rapidli
increas
titer
avid
recognit
conform
epitop
envspecif
antibodi
vaccine
enhanc
envspecif
antibodi
matur
observ
second
ttvvector
vaccin
boost
preexist
antivaccinia
vector
neutral
respons
thought
like
inhibit
induct
neutral
antibodi
encod
sarscov
glycoprotein
subsequ
inocul
mice
wildtyp
ttv
recombin
ttvvector
vaccin
howev
inhibitori
effect
result
preexposur
wildtyp
meng
et
al
ttv
via
intraderm
rout
larg
overcom
subsequ
vaccin
recombin
ttvvector
vaccin
via
heterolog
intraor
intranas
rout
fact
present
studi
neutral
antibodi
titer
wildtyp
ttv
found
rang
serum
sampl
vaccine
control
hors
wk
second
boost
observ
serum
neutral
activ
ttv
vector
second
boost
vaccin
data
shown
result
suggest
rapidli
induc
preexist
neutral
antibodi
respons
ttv
vector
might
contribut
inhibit
matur
envspecif
antibodi
second
boost
rttv
vaccin
context
immun
recombin
ttvvector
vaccin
via
heterolog
mucos
rout
may
effect
way
reduc
inhibitori
effect
improv
matur
envspecif
antibodi
increas
interv
boost
vaccin
deliv
via
rout
data
previou
studi
indic
eiav
fddv
induc
broadli
neutral
antibodi
might
confer
enhanc
protect
vaccine
infect
challeng
viru
eiav
lnv
addit
result
indic
infecti
molecular
clonederiv
eiav
strain
induc
broadli
neutral
antibodi
level
steadi
vivo
replic
compar
parent
vaccin
strain
eiav
fddv
less
divers
immunogen
composit
suggest
major
caus
fail
elicit
broadli
neutral
antibodi
agreement
previou
data
articl
found
dna
vaccin
rttv
vaccin
encod
env
gene
induc
broadli
neutral
antibodi
result
suggest
addit
env
sequenc
eiav
fddv
may
necessari
induc
broadli
neutral
antibodi
work
identif
possibl
env
sequenc
capabl
elicit
broadli
neutral
antibodi
examin
identifi
sequenc
use
dna
primerecombin
ttv
vaccin
strategi
may
aid
elucid
mechan
underli
induct
broadli
neutral
antibodi
attenu
chines
eiav
vaccin
pilot
studi
found
vaccin
regimen
base
eiav
dna
vaccin
prime
recombin
ttv
vaccin
boost
fail
protect
vaccine
death
follow
wildtyp
eiav
challeng
immatur
envspecif
antibodi
lack
broadli
neutral
antibodi
may
partial
account
protect
failur
data
may
provid
valuabl
inform
futur
work
antibodyori
lentivir
vaccin
